ZyCoV-D (DNA Vaccine)

ZyCoV-D is a plasmid DNA vaccine against SARS-CoV-2 developed by the Indian pharmaceutical company Zydus Cadila (formerly Cadila Healthcare, now Zydus Lifesciences) at its Vaccine Technology Centre in Ahmedabad. On 20 August 2021 the Drugs Controller General of India (DCGI), under the Central Drugs Standard Control Organisation (CDSCO), granted it Emergency Use Authorisation, making it the world's first DNA vaccine approved for human administration. The development was partially funded by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) under the National Biopharma Mission and the Mission COVID Suraksha programme. Its regulatory clearance under the New Drugs and Clinical Trials Rules, 2019, represented a landmark for India's indigenous biotechnology capacity, distinguishing ZyCoV-D from contemporaneous platforms such as the inactivated-virus Covaxin and the viral-vector Covishield.

The vaccine functions by introducing a small, circular fragment of engineered DNA — a plasmid — encoding the spike (S) protein of SARS-CoV-2 along with a promoter region that drives its expression. Once the plasmid enters a host cell and reaches the nucleus, the cellular machinery transcribes it into messenger RNA, which is then translated in the cytoplasm into the spike antigen. The immune system recognises this antigen as foreign and mounts both humoral (antibody) and cellular (T-cell) responses, generating immunological memory without exposure to the live or inactivated pathogen. Because the plasmid remains episomal and does not integrate into the host genome, the platform was characterised by its developers as carrying a low risk of insertional mutagenesis.

A defining mechanical feature of ZyCoV-D is its delivery system: it is administered intradermally through a needle-free injector, the PharmaJet Tropis device, which uses a narrow, pressurised stream of fluid to deposit the vaccine into the dermal layer rather than a hypodermic needle into muscle. This reduces injection-site pain, eliminates needle-stick injuries and sharps waste, and improves uptake into antigen-presenting cells abundant in the skin. The original regimen comprised three doses administered on days 0, 28 and 56. In 2022 Zydus received approval for a two-dose regimen of a higher-strength formulation, simplifying logistics and reducing the cold-chain burden, since the product is stable at 2–8°C and demonstrated stability at 25°C for several months.

ZyCoV-D was authorised initially for individuals aged 12 years and above, making it among the first COVID-19 vaccines in India cleared for adolescents. Its Phase III efficacy trial, conducted across roughly 50 sites in India during the Delta-variant wave, enrolled over 28,000 participants and reported an interim efficacy of approximately 67 percent against symptomatic disease. The Union Ministry of Health and Family Welfare incorporated ZyCoV-D into procurement plans, and the Government of India placed orders for crores of doses. Manufacturing scale-up was supported at Zydus's facilities in Gujarat, with the company targeting an annual capacity of 100–120 million doses. The vaccine's rollout, however, remained limited relative to Covishield and Covaxin owing to logistics and timing.

ZyCoV-D must be distinguished from adjacent vaccine platforms. Unlike an mRNA vaccine such as Pfizer-BioNTech's Comirnaty or Moderna's Spikevax, which delivers ready-made messenger RNA encapsulated in lipid nanoparticles directly into the cytoplasm, a DNA vaccine delivers genetic material that must first reach the cell nucleus to be transcribed, adding a step but conferring superior thermostability. Unlike viral-vector vaccines (Covishield, Sputnik V) that use a modified adenovirus as a carrier, the DNA platform uses a non-replicating bacterial plasmid, avoiding pre-existing anti-vector immunity. And unlike inactivated-virus vaccines (Covaxin, Sinovac), it contains no whole pathogen and requires no high-biosafety-level cultivation of live virus.

The platform was not without controversy and limitations. DNA vaccines had historically suffered from comparatively weak immunogenicity in humans, requiring multiple doses or specialised delivery to elicit adequate responses — a factor reflected in ZyCoV-D's original three-dose schedule. Some scientists noted that full peer-reviewed Phase III efficacy data were published only after authorisation, prompting calls for greater transparency, a recurring critique during the pandemic's accelerated regulatory environment. The needle-free injector, while advantageous, required device-specific training and supply, complicating field deployment. By 2023, as demand for primary COVID-19 vaccination declined sharply, ZyCoV-D's commercial trajectory narrowed, though the validated DNA platform retained strategic value for future pathogens and is being explored for other indications.

For the working practitioner, policy analyst, or civil-services aspirant, ZyCoV-D is significant as a proof of concept rather than merely a single product. It established that the DNA vaccine platform — long pursued in veterinary medicine and human trials without licensure — could clear human regulatory approval, expanding the global toolkit for rapid pandemic response. For India, it demonstrated indigenous end-to-end vaccine innovation, from antigen design to needle-free delivery, advancing the Atmanirbhar Bharat and Mission COVID Suraksha objectives within science-and-technology governance (UPSC GS Paper 3). Its thermostability addresses a critical cold-chain vulnerability for low- and middle-income countries. Analysts tracking biosecurity, intellectual property, and pandemic preparedness regard ZyCoV-D as a reference case for how nascent biotechnology platforms transition from laboratory promise to authorised deployment under emergency conditions.